JP2017525712A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525712A5
JP2017525712A5 JP2017510539A JP2017510539A JP2017525712A5 JP 2017525712 A5 JP2017525712 A5 JP 2017525712A5 JP 2017510539 A JP2017510539 A JP 2017510539A JP 2017510539 A JP2017510539 A JP 2017510539A JP 2017525712 A5 JP2017525712 A5 JP 2017525712A5
Authority
JP
Japan
Prior art keywords
tablet
contained
range
tablet according
azepino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017510539A
Other languages
English (en)
Japanese (ja)
Other versions
JP6574477B2 (ja
JP2017525712A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/045522 external-priority patent/WO2016028689A1/en
Publication of JP2017525712A publication Critical patent/JP2017525712A/ja
Publication of JP2017525712A5 publication Critical patent/JP2017525712A5/ja
Application granted granted Critical
Publication of JP6574477B2 publication Critical patent/JP6574477B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017510539A 2014-08-22 2015-08-17 ルカパリブの高投与力価錠剤 Active JP6574477B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019149084A Division JP6797980B2 (ja) 2014-08-22 2019-08-15 ルカパリブの高投与力価錠剤

Publications (3)

Publication Number Publication Date
JP2017525712A JP2017525712A (ja) 2017-09-07
JP2017525712A5 true JP2017525712A5 (enExample) 2018-09-27
JP6574477B2 JP6574477B2 (ja) 2019-09-11

Family

ID=55347324

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017510539A Active JP6574477B2 (ja) 2014-08-22 2015-08-17 ルカパリブの高投与力価錠剤
JP2019149084A Active JP6797980B2 (ja) 2014-08-22 2019-08-15 ルカパリブの高投与力価錠剤
JP2020191356A Active JP7127101B2 (ja) 2014-08-22 2020-11-18 ルカパリブの高投与力価錠剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019149084A Active JP6797980B2 (ja) 2014-08-22 2019-08-15 ルカパリブの高投与力価錠剤
JP2020191356A Active JP7127101B2 (ja) 2014-08-22 2020-11-18 ルカパリブの高投与力価錠剤

Country Status (24)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR20170043597A (enExample)
CN (2) CN106794185A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
ES (1) ES3048688T3 (enExample)
FI (1) FI3182975T3 (enExample)
HR (1) HRP20251484T1 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PL (1) PL3182975T3 (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
SI (1) SI3182975T1 (enExample)
SM (1) SMT202600141T1 (enExample)
WO (1) WO2016028689A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US10117836B2 (en) 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
KR20170043597A (ko) * 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
EP3573990B1 (en) 2017-01-24 2024-07-10 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
CN111278433A (zh) * 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
AU2019205325A1 (en) 2018-01-05 2020-08-13 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
BR112022000297A2 (pt) 2019-07-10 2022-03-15 Cybrexa 3 Inc Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
ES3051838T3 (en) 2020-07-14 2025-12-30 Assia Chem Ind Ltd Solid state forms of rucaparib salts
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022215034A1 (en) 2021-04-08 2022-10-13 Rhizen Pharmaceuticals Ag Inhibitors of poly(adp-ribose) polymerase
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
CN118215467A (zh) * 2021-11-10 2024-06-18 克里蒂泰克公司 鲁卡帕尼颗粒及其用途
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140936B1 (en) 1999-01-11 2004-03-17 Agouron Pharmaceuticals, Inc. Tricyclic inhibitors of poly(adp-ribose) polymerases
JP2006522088A (ja) 2003-03-31 2006-09-28 ファイザー・インク ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩
MXPA06000993A (es) 2003-07-25 2006-08-31 Cancer Rec Tech Ltd Inhbidores triciclicos de parp.
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ(adp−リボース)ポリメラーゼ阻害剤を含む治療用組成物
CA2580833C (en) 2004-09-22 2010-12-21 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
CA2581025C (en) 2004-09-22 2011-06-07 Pfizer Inc. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US20110136883A1 (en) * 2008-04-09 2011-06-09 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
ES2607806T5 (es) * 2010-02-12 2024-10-07 Pfizer Sales y polimorfos de 8-fluoro-2-{4-[(metilamino}metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona
CN104582795B (zh) 2012-04-05 2018-04-20 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
KR20170043597A (ko) 2014-08-22 2017-04-21 클로비스 온콜로지 인코포레이티드 루카파립의 고 용량 강도 정제

Similar Documents

Publication Publication Date Title
RU2017109139A (ru) Таблетки, содержащие большую дозу рукапариба
TWI583384B (zh) 包含4-胺基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸鹽單水合物之醫藥組合物
JP7023945B2 (ja) レナリドミドの経口用錠剤組成物
JP6245677B2 (ja) 口腔内崩壊錠
JP2011098964A5 (enExample)
ES2311442T1 (es) Dosis en forma oral.
WO2015132708A1 (en) Pharmaceutical composition of roflumilast
CN104661649A (zh) 包含替格瑞洛的固态口服医药制剂
WO2015029074A2 (en) Compositions of eltrombopag
WO2015071432A1 (en) Pharmaceutical compositions of ibrutinib
JP2015521191A5 (enExample)
CN101478966B (zh) 压缩制剂
CA2764172A1 (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
CN101312714A (zh) 替米沙坦的药用组合物
KR20180083239A (ko) 리마프로스트 또는 리마프로스트 알파엑스를 함유한 경구용 서방성 제제 조성물
WO2014058046A1 (ja) カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤
CA2833115C (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
WO2014058047A1 (ja) カルシウム拮抗薬/アンジオテンシンii受容体拮抗薬含有医薬製剤の製造方法
JP2019532960A (ja) エソメプラゾール含有複合カプセル剤及びその製造方法
WO2011080706A1 (en) Enhanced solubility of ziprasidone
KR20100083047A (ko) 생체이용률이 향상된 발사르탄을 포함하는 약제학적 조성물
WO2016012898A1 (en) Oral pharmaceutical composition of lurasidone
JP2016539109A (ja) イソニアジドの顆粒およびリファペンチンの顆粒を含むコーティング錠の形態の抗結核性の安定な医薬組成物ならびにその製造方法
JP5241511B2 (ja) 溶出性の改善された医薬組成物